Frontiers in Cancer Immunotherapy

Frontiers in Cancer Immunotherapy

Monday, February 27, 2017 - Tuesday, February 28, 2017

The New York Academy of Sciences

Presented By

The Mushett Family Foundation

Science

Science Immunology

Science Translational Medicine

The New York Academy of Sciences

 

Cancer immunotherapy—the use of the immune system to treat cancer—is one of the most promising therapies to emerge since the development of chemotherapy in the mid-twentieth century. Harnessing the body's own innate defense mechanisms to attack cancer cells has demonstrated potential for developing treatments that are not only more efficacious (including long-lasting remissions and progression-free survival rates), but also more precise. Importantly, increased precision may reduce the toxicity that is often experienced with current pharmaceutical interventions. Different immunotherapeutic approaches, ranging from activating the patient's own immune response to attack cancer cells to neutralizing mechanisms designed to regulate and suppress patient's immune systems, are increasingly implemented in the regimen of oncology clinical care with positive results.

This 2-day scientific symposium will explore emerging findings in basic science, translational research, and clinical studies to improve immunotherapeutic approaches in cancer treatment. The event will convene basic, preclinical, and clinical researchers active in the field of cancer immunotherapy, alongside industry representatives and government stakeholders. Dr. Padmanee Sharma, Professor of Genitourinary Medical Oncology and of Immunology at the University of Texas MD Anderson Cancer Center, will commence the conference with a Keynote Address. Plenary speakers will present on an array of topics, including: the evaluation of combination therapy strategies to improve clinical benefit; the development of immune-monitoring strategies for the identification of relevant prognostic and predictive biomarkers; the development of strategies to overcome immune tolerance; and the incorporation of genomics into immunotherapeutic research and clinical trials.

Registration Pricing

By 2/3/2017After 2/3/2017Onsite
Member$175$200$250
Student/Postdoc Member$150$175$225
Nonmember (Academia)$250$300$375
Nonmember (Corporate)$350$400$475
Nonmember (Non-profit)$250$300$375
Nonmember (Student/Postdoc/Fellow)$175$200$350

Paid registration includes a complimentary, one-year membership to the New York Academy of Sciences. Complimentary memberships are provided to non-members only and cannot be used to renew or extend existing or expiring memberships. A welcome email will be sent upon registration which will include your membership credentials.

On March 1, 2017, The New York Academy of Sciences' Cancer and Signaling Discussion Group will present a satellite symposium titled, Quantitative Approaches in Immuno-Oncology. This symposium will explore the emerging field of quantitative immuno-oncology, covering the breadth of scientific topics and methods needed to quantify interactions between tumors and the immune system.

To learn more and register, visit www.nyas.org/QIO2017.

Sponsors

For sponsorship opportunities please contact Kari Fischer, PhD, at kfischer@nyas.org or 212.298.8648.

Grant Support

This program is supported in part by educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech, Incyte, and Prometheus Laboratories Inc.

Gold Sponsor

Mushett Family Foundation

Bronze Sponsors

Ono Pharmaceutical Co., Ltd.

Tesaro, Inc.

Academy Friend

Inovio Pharmaceuticals, Inc.

Promotional Partners

Damon Runyon Cancer Research Foundation

The Cancer Journal

American Journal of Clinical Oncology

Journal of Cellular Immunotherapy

Journal of Immunotherapy

Nature Immunology

Nature Reviews Cancer

Wolters Kluwer

Presented by

Mushett Family FoundationScience
Science ImmunologyScience Translational Medicine
The New York Academy of Sciences

Agenda

* Presentation titles and times are subject to change.


Day 1: February 27, 2017

7:45 AM

Breakfast and Registration

8:30 AM

Introduction and Welcome Remarks
Angela Colmone, PhD, representing Science, Science Translational Medicine, and Science Immunology
Melanie Brickman Borchard, PhD, MSc, The New York Academy of Sciences

8:55 AM

Keynote Address:
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
Padmanee Sharma, MD, PhD, The University of Texas MD Anderson Cancer Center

Session 1: Assessment of Current Therapeutic Approaches in Cancer Immunotherapy: Successes and Challenges

Session Chair: Jedd D. Wolchok, MD, Memorial Sloan Kettering Cancer Center

9:40 AM

Engineering T Cells to Be Effective in Tumor Therapy
Philip D. Greenberg, MD, University of Washington

10:05 AM

Modulation of Immunity through Dendritic Cell Targeting
Nina Bhardwaj, MD, PhD, Mount Sinai School of Medicine

10:30 AM

Treating the Tumor and Treating the Host
Ronald Levy, MD, Stanford University

10:55 AM

Networking Coffee Break

Session 2: Evaluation of Combination Therapy Strategies to Improve Clinical Outcomes

Session Chair: Michele Maio, PhD, University Hospital, Sienna

11:25 AM

Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms
Jedd D. Wolchok, MD, Memorial Sloan Kettering Cancer Center

11:50 AM

The Promise of Epigenetic Therapies for Enhancing the Efficacy of Immune Checkpoint Therapy
Stephen B. Baylin, MD, Johns Hopkins University

12:15 PM

Therapeutic Vaccination for Premalignant HPV Disease: It's Getting Better All the Time
Cornelia (Connie) Liu Trimble, MD, Johns Hopkins University

12:40 PM

Networking Lunch and Poster Viewing

12:55 PM

Underrepresented Minorities, Women, and Early Career Investigator Career Development Workshop and Lunch Running Concurrently with the Networking Lunch 
For Graduate Students, Post-doctoral Fellows, and Junior Faculty

Editor's Guide to Writing and Publishing Your Paper
Angela Colmone, PhD, Editor, Science Immunology
Priscilla Kelly, PhD, Associate Editor, Science
Yevgeniya Nusinovich, MD, PhD, Senior Editor, Science Translational Medicine

Session 3: Identification of Relevant Prognostic and Predictive Biomarkers for the Development of Immune-Monitoring Strategies

Session Chair: Angela Colmone, PhD, Science Immunology

2:00 PM

Inflammation and Cancer: Fueling Response and Resistance of Immunotherapies
Lisa Coussens, PhD, Oregon Health Sciences University

2:25 PM

T cell Receptor Responses in Health and Disease
Mark Davis, PhD, Stanford University

2:50 PM

Melanoma Response and Resistance to PD-1 Blockade Therapy
Antoni Ribas, MD, PhD, University of California Los Angeles

3:15 PM

Networking Coffee Break

Session 4: Development of Strategies to Overcome Immune Tolerance

Session Chair: Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute

3:40 PM

Tumor and Host Pathways that Shape Degrees of Immunotherapy Resistance
Thomas Gajewski, MD, PhD, University of Chicago

4:05 PM

Molecular and Epigenetic Programs Underlying CD8 T Cell Dysfunction in Solid Tumors
Andrea Schietinger, PhD, Memorial Sloan Kettering Cancer Center

4:30 PM

Targeting FoxP3+ T-cells in Cancers; Friends or Foes?
Hiroyoshi Nishikawa, MD, PhD, National Cancer Center Hospital, Japan

4:55 PM

Emerging Technologies in Cancer Immunotherapy
Carl June, MD, University of Pennsylvania

5:20 PM

Panel Discussion — Day 1 Wrap-up 
Moderator: Yevgeniya Nusinovich, MD, PhD, Science Translational Medicine
 
Panelists:

Philip D. Greenberg, MD, University of Washington
Connie Trimble, MD, Johns Hopkins University
Mark Davis, PhD, Stanford University
Carl June, MD, University of Pennsylvania

5:45 PM

Closing Remarks

5:55 PM

Poster Session 1 and Networking Reception

7:00 PM

Day 1 Adjourns

Day 2: February 28, 2017

8:00 AM

Breakfast and Registration

8:00 AM

Underrepresented Minorities, Women, and Early Career Investigator Mentoring Breakfast Running Concurrently with the General Breakfast

Mentors:
•   Stephen B. Baylin, MD, Johns Hopkins University
•   Michele Maio, PhD, University Hospital, Sienna
•   Crystal Mackall, MD, Stanford University

Session 5: Clinical Research Break Out Sessions

9:00 AM

Breakout Group 1: How to Manage Toxicities in Cancer Immunotherapy?
Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center

Breakout Group 2: How to Incorporate Biomarkers into Early Phase Immunotherapy Trials?
Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute
Sacha Gnjatic, PhD, Mount Sinai School of Medicine

Breakout Group 3: What are the Latest Strategies for Cancer Immunotherapy Development — a Pharmaceutical Industry Perspective?
Ira Mellman, PhD, Genentech

10:00 AM

Networking Coffee Break

Session 6: Optimizing Incorporation of Cancer Genomics and Epigenomics into Immunotherapy Research and Clinical Strategies

Session Chair: Laurence Zitvogel, MD, PhD, Institut National de la Santé et Recherche Médicale

10:30 AM

T-cell Adoptive Therapy Moves Beyond Melanoma
James C. Yang, MD, National Cancer Institute, U.S. National Institutes of Health

10:55 AM

Epigenetic Immunomodeling for Cancer Immunotherapy
Michele Maio, PhD, University Hospital, Sienna

11:20 AM

Immunotherapeutic Responses to Cancer Neoantigens
Matthew Gubin, PhD, Washington University

11:45 AM

Networking Lunch and Poster Session 2

Session 7: Targeting T-cells in Cancer Immunotherapy

Session Chair: Philip D. Greenberg, MD, University of Washington

1:15 PM

Regulatory T-cells and Strategies for Inhibition for Cancer Therapy
Alexander Rudensky, PhD, Memorial Sloan Kettering Cancer Center

1:40 PM

Chimeric Antigen Receptors: Progress and Challenges
Crystal Mackall, MD, Stanford University

2:05 PM

Targeting Tryptophan Metabolism to Overcome Negative Regulation of Antitumor Immunity in Ovarian Cancer
Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute

2:30 PM

Networking Coffee Break

Session 8: Hot Topic Short Talks

Session Chair: Hiroyoshi Nishikawa, MD, PhD, National Cancer Center Hospital, Japan

3:00 PM

Activating the Brain to Fight Cancer: Reward System Activation Attenuates Tumor Growth in Mice
Tamar Ben-Shaanan, MsC, Technion, Israel Institute of Technology

3:15 PM

MEX3B Mediates Resistance to T cell-based Immunotherapy by Impairing Antigen Processing and Presentation
Lu Huang, PhD, The University of Texas M.D. Anderson Cancer Center

3:30 PM

Fatty Acid Metabolism Limits an Oxidative Stress Response that Promotes T Cell Exhaustion During Rapid Clonal Proliferation
Roddy O'Connor, University of Pennsylvania

3:45 PM

Tissue-specific Efficacy and Safety of Checkpoint Blockade Combination Immunotherapy
Kavya Rakhra, PhD, Massachusetts Institute of Technology

4:00 PM

Inducing New Systemic Immune Responses and Frequent Durable Complete Regressions (CRs) of Human Metastatic Melanoma with Intralesional Secreted Cytokines
Fred T. Valentine, MD, New York University School of Medicine

Session 9: Emerging Technologies in Cancer Immunotherapy

Session Chair: Melanie Brickman Borchard, PhD, MSc, The New York Academy of Sciences

4:15 PM

Role of the Human Intestinal Microbiome in the Response to PD1 Blockade in Advanced Cancer
Laurence Zitvogel, MD, PhD, Institut National de la Santé et Recherche Médicale

4:40 PM

Closing Remarks

4:50 PM

Conference Adjourns

Organizers

James P. Allison, PhD

The University of Texas MD Anderson Cancer Center

Melanie Brickman Borchard, PhD, MSc

The New York Academy of Sciences
website

Jonathan Cebon, MBBS, PhD, FRACP

Olivia Newton-John Cancer and Wellness Centre

Angela Colmone, PhD

Science Immunology

Philip D. Greenberg, MD

University of Washington

Brooke Grindlinger, PhD

The New York Academy of Sciences
website

Priscilla Kelly, PhD

Science

Michele Maio, MD, PhD

University Hospital, Sienna

Kristen Mueller, PhD

Science

Hiroyoshi Nishikawa, MD, PhD

National Cancer Center, Japan

Yevgeniya Nusinovich, MD, PhD

Science Translational Medicine

Kunle Odunsi, MD, PhD

Roswell Park Cancer Institute

Daniel Radiloff, PhD

The New York Academy of Sciences

Jedd D. Wolchok, MD, PhD

Memorial Sloan Kettering Cancer Center

Laurence Zitvogel, MD, PhD

Institut National de la Santé et Recherche Médicale

Keynote Speaker

Padmanee Sharma, MD, PhD

The University of Texas MD Anderson Cancer Center

Speakers

Stephen B. Baylin, MD

Johns Hopkins University

Nina Bhardwaj, MD, PhD

Icahn School of Medicine at Mount Sinai

Lisa Coussens, PhD

Oregon Health Sciences University
website

Mark Davis, PhD

Stanford University

Thomas Gajewski, MD, PhD

University of Chicago

Sacha Gnjatic, PhD

Mount Sinai School of Medicine

Matthew Gubin, PhD

Washington University in St. Louis

Carl June, MD

University of Pennsylvania

Ronald Levy, MD

Stanford University
website

Crystal Mackall, MD

Stanford University

Ira Mellman, PhD

Genentech

Kunle Odunsi, MD, PhD

Roswell Park Cancer Institute

Antoni Ribas, MD, PhD

University of California Los Angeles
website

Alexander Rudensky, PhD

Memorial Sloan Kettering Cancer Center

Andrea Schietinger, PhD

Memorial Sloan Kettering Cancer Center
website

Connie Trimble, MD

Johns Hopkins University

James C. Yang, MD

National Cancer Institute, U.S. National Institutes of Health

Travel & Lodging

Our Location

The New York Academy of Sciences

7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600

Directions to the Academy

Hotels Near 7 World Trade Center

Recommended partner hotel

Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133

The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.

Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.

Other nearby hotels

Conrad New York

212.945.0100

Millenium Hilton

212.693.2001

Marriott Financial Center

212.385.4900

Club Quarters, Wall Street

212.269.6400

Eurostars Wall Street Hotel

212.742.0003

Gild Hall, Financial District

212.232.7700

Wall Street Inn

212.747.1500

Ritz-Carlton New York, Battery Park

212.344.0800